Lawreen Heller Connors

Lawreen Heller Connors

Auto-generated profile, based on publicly available information

Lawreen Heller Connors

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Amyloid
Verified
Journal Article
Closed access
PDF file
LCLawreen Heller Connors
Lawreen Heller Connors
ALAmareth Lim
Amareth Lim
TPTatiana Prokaeva
Tatiana Prokaeva
VRViolet A. Roskens
Violet A. Roskens
CCCatherine E Costello
Catherine E Costello
(2003). Tabulation of human transthyretin (TTR) variants, 2003. Amyloid: Vol. 10, No. 3, pp. 160-184. doi: 10.3109/13506120308998998

30 April 2004 in Circulation Research
Verified
Journal Article
Closed access
PDF file
DBDaniel A. Brenner
Daniel A. Brenner
MJMohit Jain
Mohit Jain
DPDavid R. Pimentel
David R. Pimentel
BWBo Wang
Bo Wang
LCLawreen H. Connors
Lawreen H. Connors
RLRonglih Liao
Ronglih Liao
Primary amyloidosis is a systemic disorder characterized by the clonal production and tissue deposition of immunoglobulin light chain (LC) proteins. Congestive heart failure remains the greatest cause of death in primary amyloidosis, due to the development of a rapidly progressive amyloid cardiomyopathy. Amyloid cardiomyopathy is largely unresponsive to current heart failure therapies, and is associated with a median survival of less than 6 months and a 5-year survival of less than 10%. The mechanisms underlying this disorder, however, remain unknown. In this report, we demonstrate that physiological levels of human amyloid LC proteins, isolated from patients with amyloid cardiomyopathy (cardiac-LC), specifically alter cellular redox state in isolated cardiomyocytes, marked by an increase in intracellular reactive oxygen species and upregulation of the redox-sensitive protein, heme oxygenase-1. In contrast, vehicle or control LC proteins isolated from patients without cardiac involvement did not alter cardiomyocyte redox status. Oxidant stress imposed by cardiac-LC proteins further resulted in direct impairment of cardiomyocyte contractility and relaxation, associated with alterations in intracellular calcium handling. Cardiomyocyte dysfunction induced by cardiac-LC proteins was independent of neurohormonal stimulants, vascular factors, or extracellular fibril deposition, and was prevented through treatment with a superoxide dismutase/catalase mimetic. This study suggests that cardiac dysfunction in amyloid cardiomyopathy is directly mediated by LC protein-induced cardiomyocyte oxidant stress and alterations in cellular redox status, independent of fibril deposition. Antioxidant therapies or treatment strategies aimed at eliminating circulating LC proteins may therefore be beneficial in the treatment of this fatal disease.

11 February 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJianru Shi
Jianru Shi
JGJian Guan
Jian Guan
BJBingbing Jiang
Bingbing Jiang
DBDaniel A. Brenner
Daniel A. Brenner
FMFederica del Monte
Federica del Monte
RLRonglih Liao
Ronglih Liao
Patients with primary (AL) cardiac amyloidosis suffer from progressive cardiomyopathy with a median survival of less than 8 months and a 5-year survival of <10%. Contributing to this poor prognosis is the fact that these patients generally do not tolerate standard heart failure therapies. The molecular mechanisms underlying this deadly form of heart disease remain unclear. Although interstitial amyloid fibril deposition of Ig light chain proteins is a major cause of cardiac dysfunction in AL cardiac amyloidosis, we have previously shown that amyloid precursor proteins directly impair cardiac function at the cellular and isolated organ levels, independent of fibril formation. In this study, we report that amyloidogenic light chain (AL-LC) proteins provoke oxidative stress, cellular dysfunction, and apoptosis in isolated adult cardiomyocytes through activation of p38 mitogen-activated protein kinase (MAPK). AL-LC–induced p38 activation was found to be independent of the upstream MAPK kinase, MKK3/6, and instead depends upon transforming growth factor-β-activated protein kinase-1 binding protein-1 (TAB1)-mediated p38α MAPK autophosphorylation. Treatment of cardiomyocytes with SB203580, a selective p38 MAPK inhibitor, significantly attenuated AL-LC–induced oxidative stress, cellular dysfunction, and apoptosis. Our data provide a unique mechanistic insight into the pathogenesis of AL-LC cardiac toxicity and suggest that TAB1-mediated p38α MAPK autophosphorylation may serve as an important event leading to cardiac dysfunction and subsequent heart failure.

27 June 2005 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
BNBelinda Ng
Belinda Ng
LCLawreen H. Connors
Lawreen H. Connors
RDRavin Davidoff
Ravin Davidoff
MSMartha Skinner
Martha Skinner
RFRodney H. Falk
Rodney H. Falk
Research from JAMA Internal Medicine — Senile Systemic Amyloidosis Presenting With Heart Failure — A Comparison With Light Chain–Associated Amyloidosis

19 January 2016 in Circulation
Verified
Journal Article
Closed access
PDF file
LCLawreen H. Connors
Lawreen H. Connors
FSFlora Sam
Flora Sam
MSMartha Skinner
Martha Skinner
FSFrancesco Salinaro
Francesco Salinaro
FSFangui Sun
Fangui Sun
DSDavid C. Seldin
David C. Seldin
Background—: Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciated cause of morbidity and mortality in the aging population. The aims of this study were to examine features of disease and to characterize outcomes in a large ATTRwt cohort. Methods and Results—: Over 20 years, 121 patients with ATTRwt were enrolled in a prospective, observational study. Median age at enrollment was 75.6 years (range, 62.6–87.8 years); 97% of patients were white. The median survival, measured from biopsy diagnosis, was 46.69 months (95% confidence interval, 41.95–56.77); 78% of deaths were attributable to cardiac causes. By Kaplan–Meier analysis, 5-year survival was 35.7% (95% confidence interval, 25–46). Impaired functional capacity (mean V o 2 max, 13.5 mL·kg −1 ·min −1 ) and atrial fibrillation (67%) were common clinical features. Multivariate predictors of reduced survival were elevated serum brain natriuretic peptide (482±337 pg/mL) and uric acid (8.2±2.6 mg/dL), decreased left ventricular ejection fraction (50% median; range, 10%–70%), and increased relative wall thickness (0.75±0.19). Conclusions—: In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atrial arrhythmias were common clinical features. Elevated brain natriuretic peptide and uric acid, decreased left ventricular ejection fraction, and increased relative wall thickness were associated with limited survival of only 35.7% at 5 years for the group as a whole. These data establish the natural history of ATTRwt, provide statistical basis for the design of future interventional clinical trials, and highlight the need for more sensitive diagnostic tests and disease-specific treatments for this disease.

2 October 2001 in Circulation
Verified
Journal Article
Closed access
PDF file
RLRonglih Liao
Ronglih Liao
MJMohit Jain
Mohit Jain
PTPaige Teller
Paige Teller
LCLawreen H. Connors
Lawreen H. Connors
SNSoeun Ngoy
Soeun Ngoy
CACarl S. Apstein
Carl S. Apstein
Background Primary (AL) amyloidosis is a plasma cell dyscrasia characterized by clonal production of immunoglobulin light chains (LC) resulting in the subsequent systemic deposition of extracellular amyloid fibrils. Cardiac involvement is marked by the hemodynamic pattern of impaired diastolic filling and restrictive cardiomyopathy. Although cardiac death in patients with AL amyloidosis is usually associated with extensive myocardial infiltration, the infiltration alone does not correlated with the degree of heart failure or survival. We hypothesized that circulating monoclonal LC may directly impair cardiac function, in addition to any mechanical effects of amyloid fibril deposition. Therefore, we examined the effects of amyloid LC proteins on diastolic and systolic cardiac function, as measured in an isolated mouse heart model. Methods and Results LC were obtained from patients with nonamyloid disease or from those with noncardiac, mild cardiac, and severe cardiac involved AL amyloidosis. Saline or LC (100 μg/mL) was infused into a Langendorff-perfused, isovolumically contracting mouse heart. Saline and control, noncardiac, and mild-cardiac LC infusions did not alter ex vivo cardiac function. In contrast, infusion of sever cardiac LC resulted in marked impairment of ventricular relaxation with preservation of contractile function. Conclusion These results demonstrate that infusion of LC from patients with AL amyloidosis result in diastolic dysfunction similar to that observed in patients with cardiac involved AL amyloidosis, and they suggest that amyloid LC proteins may contribute directly to the pathogenesis and the rapid progression of amyloid cardiomyopathy, independent of extracellular fibril deposition.